These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26489545)

  • 1. [Current Status and Perspective of Chemoradiotherapy for Uterine Cervical Cancer].
    Toita T; Ariga T; Kasuya G; Hashimoto S; Maemoto H; Heianna J; Kakinohana Y; Murayama S
    Gan To Kagaku Ryoho; 2015 Oct; 42(10):1156-61. PubMed ID: 26489545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
    DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis.
    Jung J; Park G; Kim YS
    Anticancer Res; 2014 Aug; 34(8):4361-6. PubMed ID: 25075072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-arm confirmatory trial of postoperative concurrent chemoradiotherapy using intensity modulated radiation therapy for patients with high-risk uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402).
    Murakami N; Isohashi F; Hasumi Y; Kasamatsu T; Okamoto H; Nakamura K; Shibata T; Ito Y; Ishikura S; Nishimura Y; Yaegashi N; Toita T
    Jpn J Clin Oncol; 2019 Sep; 49(9):881-885. PubMed ID: 31613355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.
    Chen MF; Tseng CJ; Tseng CC; Yu CY; Wu CT; Chen WC
    Cancer J; 2008; 14(3):200-6. PubMed ID: 18536561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
    Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.
    Chen CC; Lin JC; Jan JS; Ho SC; Wang L
    Gynecol Oncol; 2011 Jul; 122(1):9-13. PubMed ID: 21514629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil chemotherapy with concurrent radiotherapy in patients with locoregionally advanced cervical carcinoma.
    Nedovic J; Protrka Z; Ninkovic S; Mitrovic S; Vojinovic R; Glisic J; Markovic-Filipovic B; Milosevic B; Peulic M; Cvetkovic A
    J BUON; 2012; 17(4):740-5. PubMed ID: 23335535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].
    Besson N; Touboul E; Daraï É; Lefranc JP; Monnier L; Schlienger M; Huguet F
    Cancer Radiother; 2014 Mar; 18(2):83-8. PubMed ID: 24462252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Locally advanced cervical cancer: Should intensity-modulated radiotherapy replace brachytherapy?].
    Mazeron R; Gilmore J; Khodari W; Dumas I; Haie-Méder C
    Cancer Radiother; 2011 Oct; 15(6-7):477-83. PubMed ID: 21880534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
    Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
    Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.
    Kirchheiner K; Nout RA; Tanderup K; Lindegaard JC; Westerveld H; Haie-Meder C; Petrič P; Mahantshetty U; Dörr W; Pötter R
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):88-95. PubMed ID: 24725693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy.
    Dyk P; Jiang N; Sun B; DeWees TA; Fowler KJ; Narra V; Garcia-Ramirez JL; Schwarz JK; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):794-801. PubMed ID: 25245584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous metastasis of cervical adenocarcinoma to the vulva.
    Richmond NA; Viera MH; Velazquez-Vega J; Kerdel FA
    Dermatol Online J; 2013 May; 19(5):18172. PubMed ID: 24011272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial.
    Wang X; Shen Y; Zhao Y; Li Z; Gou H; Cao D; Yang Y; Qiu M; Li Q; Liu J; Yi C; Liao Z; Luo D; Xu F; Bi F
    Eur J Surg Oncol; 2015 Aug; 41(8):1082-8. PubMed ID: 26033265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
    Kim JY; Kim JY; Kim JH; Yoon MS; Kim J; Kim YS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):741-7. PubMed ID: 22898382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.